Q-omics provides the consensus-scored PPFIA1 profile across patient tissues and cancer cell-line models. PPFIA1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PPFIA1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, PPFIA1 RNA expression shows 21,080 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where PPFIA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPFIA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPFIA1 survival associations across molecular data types. PPFIA1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPFIA1 RNA expression–survival associations across cancer types. High PPFIA1 expression shows unfavorable associations in KICH, CESC, LGG and PAAD, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PPFIA1 RNA expression.
This table summarizes PPFIA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PPFIA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPFIA1 shows higher tumor expression in HNSC, STAD, LIHC, BLCA, LUSC and BRCA. The HNSC box plot shows higher PPFIA1 RNA expression in tumor versus normal tissue (log2 FC = +1.337, t-test p < 0.001).
This table shows molecular features associated with PPFIA1 in patient tissues and cancer cell lines. In patient samples, PPFIA1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPFIA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
